학술논문

Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830]
Document Type
Erratum
Source
In Annals of Oncology August 2021 32(8):1068-1068
Subject
Language
ISSN
0923-7534